Menu
Search
|

Menu

Close
X

Oxford Immunotec Global PLC OXFD.OQ (NASDAQ Stock Exchange Global Market)

11.89 USD
-- (--)
As of Feb 21
chart
Previous Close 11.89
Open --
Volume --
3m Avg Volume 47,174
Today’s High --
Today’s Low --
52 Week High 19.50
52 Week Low 10.26
Shares Outstanding (mil) 25.65
Market Capitalization (mil) 305.04
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.60 Mean rating from 5 analysts

KEY STATS

Revenue (mm, USD)
FY17
78
FY16
86
FY15
63
EPS (USD)
FY17
-1.792
FY16
-1.000
FY15
-1.127
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
3.00
8.67
Price to Book (MRQ)
vs sector
3.93
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
38.61
15.38
LT Debt to Equity (MRQ)
vs sector
38.50
12.01
Return on Investment (TTM)
vs sector
-47.82
13.57
Return on Equity (TTM)
vs sector
-60.16
15.19

EXECUTIVE LEADERSHIP

Richard Sandberg
Independent Chairman of the Board, Since 2008
Salary: $100,000.00
Bonus: --
Peter Wrighton-Smith
Chief Executive Officer, Director, Since 2002
Salary: $370,383.00
Bonus: --
Richard Altieri
Chief Financial Officer, Since 2012
Salary: $300,000.00
Bonus: --
Stefan Linn
Chief Operating Officer, Since 2017
Salary: --
Bonus: --
Peter Edwardson
Senior Vice President & Head of Blood Screening, Since 2017
Salary: $268,518.00
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Advanced Medical Equipment & Technology
Address:

94C Innovation Drive, Milton Par
ABINGDON     OX14 4RZ

Phone: +441235.442780

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company's product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology. Its T-SPOT.TB test is used to test for tuberculosis (TB), infection and leverages its T-SPOT technology platform, which allows it to measure the response of specific immune cells to inform the diagnosis, prognosis and monitoring of patients with immune-regulated conditions. It offers a range of assays for tick-borne diseases, such as Lyme disease, obtained through the acquisitions of Imugen and Immunetics. It has a series of assays for use in blood screening, building upon its expertise in tick-borne disease. Its T-SPOT. CMV and T-SPOT. PRT tests are part of its product line focused on the transplantation market.

SPONSORED STORIES